Health
GC Biopharma Announces Presentation on Aggregation Profiles of Commercial IVIG Products at NHIA 2026
TEANECK, N.J., April 16, 2026--GC Biopharma Announces Presentation on Aggregation Profiles of Commercial IVIG Products at NHIA 2026
About this update from Gc Biopharma Corp.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":253,"url":"https://media.zenfs.com/en/business-wire.com/8de062bf0313e6b481b4c740f643e812"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VQFPTEp5.4zAHUPOAluiWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNg--/https://media.zenfs.com/en/business-wire.com/8de062bf0313e6b481b4c740f643e812","width":480,"height":253}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Research highlights molecular size distribution and particle characteristics across commercially available intravenous immunoglobulin (IVIG) products","length":149,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Protein aggregation in IVIG preparations may influence immunogenicity, stability, and infusion tolerability, underscoring the importance of controlling impurities and aggregation during IVIG manufacturing","length":204,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":353,"olType":false},{"type":"text","content":"TEANECK, N.J., April 16, 2026--(BUSINESS WIRE)--GC Biopharma USA, Inc., a leader in plasma-derived products, today announced the presentation of new research evaluating the aggregation profiles, including molecular size distribution and particle size, in commercially available intravenous immunoglobulin (IVIG) products. The data will be presented at the 2026 National Home Infusion Association (NHIA) Annual Conference, taking place April 18–22, in Denver, Colorado.","length":468,"tagName":"p"},{"type":"text","content":"Global demand for IVIG has increased steadily due to improved recognition of primary immunodeficiencies and broader use in immune-mediated conditions. As utilization expands, manufacturing processes must balance immunoglobulin yield with product purity, stability, and safety. Protein aggregates are an important consideration in IVIG products, as they may influence immunogenicity, stability, and infusion-related reactions, highlighting the importance of monitoring impurities and aggregation during manufacturing.","length":516,"tagName":"p"},{"type":"text","content":""Immunoglobulin therapy is the gold standard for the treatment of primary immunodeficiency and other immune-mediated conditions," said Alan Huber, PharmD, Director of...